The Coming Bust

The Coming Bust

The Coming Bust

I'm sure you've noticed that telemedicine is the new thing.

It's always a lot more enticing to get in on an investment sooner rather than later -- buy early, and your long-term returns could be far greater. Teladoc Health (NYSE:TDOC) is an example of a stock that's been dominating the markets for years, and it's already up more than 130% in 2020. The S&P 500, by comparison, is still down 6% year to date.

But while the virtual health services provider is certainly an attractive investment, its shares have gotten a lot pricier. With the stock doing as well as it has this year, it's now trading at 24 times its revenue and more than 15 times its book value. And that's why instead of buying Teladoc, investors may want to consider investing in an upcoming IPO that could enjoy similar success: Amwell.

This wouldn't be first time in American economic history that "irrational exuberance" has reared its ugly head.

In his book, The Hard Thing About Hard Things. Ben Horowitz share his tales from the tech trenches and reminds us of the ups and downs of the tech sector. The same could be happening before our COVID eyes. Why?

  1. While telemedicine is convenient, it does not address the fundamental flaws of the US Sickcare system of systems
  2. It is questionable whether the accelerated waiver of rules and regulations will persist
  3. There are significant gaps between the values of doctors and the values of patients
  4. VAST business models have not been validated
  5. Medical education is way behind training students and residents digital health
  6. The barriers to widespread dissemination and implementation persist
  7. Systems consolidation will drive up prices and drive down salaries for doctors
  8. Integrating AI, remote sensing, patient-reported outcomes and the IoMT will be increasingly difficult
  9. The quality of telemedicine is suspect as is face to face care
  10. Nontraditional entrants, like telecom, cable, BIG PHARMA and BIG TECH are eating at market share

Did you invest in NETSCAPE or Loudcloud?

Arlen Meyers, MD, MBA is the President and CEO of the Society of Physician Entrepreneurs and advisor at

Share this article

Leave your comments

Post comment as a guest

terms and condition.
  • Paul Genockey

    Healthcare stocks are overpriced !

  • Suzanne Revill

    Interesting read

  • Julian Fogg

    Health care services are the only things I buy where I don't know the price before I buy it.

  • Benjamin Janissen

    Very interesting

Share this article

Arlen Meyers, MD, MBA

Former Contributor

Arlen Meyers, MD, MBA is a professor emeritus of otolaryngology, dentistry, and engineering at the University of Colorado School of Medicine and the Colorado School of Public Health and President and CEO of the Society of Physician Entrepreneurs at He has created several medical device and digital health companies. His primary research centers around biomedical and health innovation and entrepreneurship and life science technology commercialization. He consults for and speaks to companies, governments, colleges and universities around the world who need his expertise and contacts in the areas of bio entrepreneurship, bioscience, healthcare, healthcare IT, medical tourism -- nationally and internationally, new product development, product design, and financing new ventures. He is a former Harvard-Macy fellow and In 2010, he completed a Fulbright at Kings Business, the commercialization office of technology transfer at Kings College in London. He recently published "Building the Case for Biotechnology." "Optical Detection of Cancer", and " The Life Science Innovation Roadmap". He is also an associate editor of the Journal of Commercial Biotechnology and Technology Transfer and Entrepreneurship and Editor-in-Chief of Medscape. In addition, He is a faculty member at the University of Colorado Denver Graduate School where he teaches Biomedical Entrepreneurship and is an iCorps participant, trainer and industry mentor. He is the Chief Medical Officer at and and Chairman of the Board at GlobalMindED at, a non-profit at risk student success network. He is honored to be named by Modern Healthcare as one of the 50 Most Influential Physician Executives of 2011 and nominated in 2012 and Best Doctors 2013.

Cookies user prefences
We use cookies to ensure you to get the best experience on our website. If you decline the use of cookies, this website may not function as expected.
Accept all
Decline all
Read more
Tools used to analyze the data to measure the effectiveness of a website and to understand how it works.
Google Analytics